| Level I | Good quality evidence |
Systematic review of RCTs with consistent findings High quality individual RCT |
| Level II |
Limited quality patient orientated evidence |
Systematic review of lower quality studies or studies with inconsistent findings Low quality clinical trial Cohort studies Case-control studies |
| Level III | Other |
Consensus guidelines, extrapolations from bench research, usual practice, opinion, disease-oriented evidence (intermediate or physiologic outcomes only), or case series |
[16] MIdazolam, IM (children-status epilepticus): National Department of Health: Affordable Medicines, EDP-PHC level. Medicine review: Midazolam, IM vs other benzodiazepines (any route of administration), 31 August 2017. http://health.gov.za/
MIdazolam, IM (children-status epilepticus): Jain P, Sharma S, Dua T, Barbui C, Das RR, Aneja S. Efficacy and safety of anti-epileptic drugs in patients with active convulsive seizures when no IV access is available: Systematic review and meta-analysis. Epilepsy research. 2016;122:47-55. https://www.ncbi.nlm.nih.gov/pubmed/26922313
Midazolam, IM (children-status epilepticus): Momen AA, Azizi Malamiri R, Nikkhah A, Jafari M, Fayezi A, Riahi K, et al. Efficacy and safety of intramuscular midazolam versus rectal diazepam in controlling status epilepticus in children. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 2015;19(2):149-54. https://www.ncbi.nlm.nih.gov/pubmed/18166545